VANCOUVER, British Columbia, March 6, 2015 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR), a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), today announced that Patrick T. Higgins, Tekmira's COO, and Mike McElhaugh, Tekmira's Chief Business Officer, will participate in an analyst-led fireside chat at the 2015 Barclays Global Healthcare Conference on Wednesday, March 11, 2015 at 10:05 – 10:30 pm (PT) / 1:05 pm – 1:30 pm (ET) in the Americana Salon 2 at The Loews Miami Beach Hotel in Miami, Florida. Webcast Information A live webcast of the fireside chat can be accessed through the Investor Section of Tekmira's website at www.tekmira.com. A webcast replay of the presentation will be available on the Tekmira website following the event. About Tekmira Tekmira Pharmaceuticals Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV). Our strategy is to target the three pillars necessary to develop a curative regimen for HBV, including suppressing HBV replication within liver cells, stimulating and reactivating the body's immune system so that it can mount an effective defense against the virus and, most importantly, eliminating the reservoir of viral genomic material known as covalently closed circular DNA, or cccDNA, that is the source of HBV persistence. Our portfolio of assets includes eight drug candidates for use in combination to develop a cure for HBV, and includes our product TKM-HBV currently in Phase 1 clinical studies. We are also developing a pipeline of oncology, anti-viral and metabolic therapeutics that leverage our expertise in RNA interference (RNAi) therapeutics and leading Lipid Nanoparticle (LNP) technology. RNAi and LNP technology have the potential to generate new therapeutics that take advantage of the body's own natural processes to silence disease causing genes, or more specifically, to eliminate specific gene-products, from the cell. We intend to continue the clinical development of TKM-PLK1 for advanced gastrointestinal neuroendocrine tumors, adrenocortical carcinoma and hepatocellular carcinoma; and TKM-Ebola, and TKM-Ebola-Guinea for ebola virus disease. Our metabolic programs and TKM-Marburg are in pre-clinical development.
With a proven management team and scientific leadership in antiviral and RNAi drug discovery and development, we are developing a robust pipeline of products with the goal of optimizing value for our shareholders and partners, and to serve patients worldwide. Tekmira is headquartered in Vancouver, BC, Canada with offices in Doylestown, PA, USA. For more information, visit www.tekmira.com.
CONTACT: Investors Julie P. Rezler Director, Investor Relations Phone: 604-419-3200 Email: firstname.lastname@example.org Media Please direct all media inquiries to: email@example.com